Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1998; 32:1068-1073
© 1998 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ricciardi, M. J.
Right arrow Articles by Rubenfire, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ricciardi, M. J.
Right arrow Articles by Rubenfire, M.

Inhaled nitric oxide in primary pulmonary hypertension

A safe and effective agent for predicting response to nifedipine

Mark J. Ricciardi, MDa, Bradley P. Knight, MDa, Fernando J. Martinez, MDb and Melvyn Rubenfire, MD, FACCa

a Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA
b Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA



View larger version (14K):

[in a new window]
 
Figure 1 A plot of the reduction in pulmonary vascular resistance (PVR) with NO and nifedipine is shown. The three patients with nifedipine hypotension were assigned PVR reduction of 0% (i.e., fixed PVR).

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement